NCT02076841 - Tolerability and Quality of Life Study in Participants Who Switched to Avonex Pen | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

October 31, 2016

Conditions

Relapsing-Remitting Multiple SclerosisClinical Isolated Syndrome (CIS)Multiple Sclerosis

Interventions

DEVICE

interferon beta-1a

Administered as specified in the treatment arm

Trial Locations (11)

Research Site, Brno

Research Site, Hradec Králové

Research Site, Jihlava

Research Site, Pilsen

Research Site, Prague

Research Site, Teplice

Research Site, Biel/Bienne

Research Site, Langenthal

Research Site, Lugano

Research Site, Sion

Research Site, Wil